Učitavanje...
Second-line treatment of hepatocellular carcinoma: from theory to practical issues
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with unmet needs of effective medications. Lenvatinib – a new oral multikinase inhibitor (MKI) proved to be as effective as sorafenib in terms of survival has been added recently to standard first-line treatment of advanced HCC...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Russo |
| Izdano: |
Remedium Group LLC
2019-12-01
|
| Serija: | Медицинский совет |
| Teme: | |
| Online pristup: | https://www.med-sovet.pro/jour/article/view/5058 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|